Ulcerative Colitis: The Complete Guide to Medical Management

Gary R. Lichtenstein, MD, FACP, FACG, AGAF

Chapter 13: Current and Future Oral Mesalamine Derivative Use in Ulcerative Colitis (continued)

Lloyd Sutherland, MDCM, MSc, FRCP(C), FACP

CURRENT AND FUTURE ORAL MESALAMINE DERIVATIVE USE IN ULCERATIVE COLITIS The modern era for the therapy of inflammatory bowel disease (IBD) began with the work of Nana Svartz, a Swedish physician with an interest in rheumatoid arthritis and ulcerative colitis. She invited her local pharmaceutical company to produce a compound with both anti-inflammatory and antibiotic properties (based on the understanding at that time). Her observations of the effect of the new compound, sulfasalazine (SASP), on disease activity in patients with UC were published in 1942.1 They provided the first effective…